Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26446040 | 0.86 | SMN1; SMN2 (0.46) | MAPTNPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL1743554 | 0.83 | ALDH1A1 (0.48) | ELANEMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17355713 | 0.81 | ELANE (0.51) | ELANENPC1RAB9AKMT2A | |
| SCHEMBL1743550 | 0.81 | ALDH1A1 (0.50) | ELANERAB9AALDH1A1KDM4EPKM | |
| SCHEMBL14254804 | 0.79 | MAPT (0.59) | MAPTSMN1; SMN2GAAPOLBMDM4 | |
| SCHEMBL26428675 | 0.79 | ELANE (0.38) | ELANEMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17845364 | 0.78 | ALDH1A1 (0.49) | MAPTRAB9AGAAMDM4TP53 | |
| SCHEMBL23417965 | 0.76 | KDM4E (0.52) | MAPTNPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL13009074 | 0.76 | KMT2A (0.46) | MAPTNPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL29177224 | 0.75 | ALDH1A1 (0.47) | MAPTNPC1RAB9ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238436-A1 | COMPOSITIONS INCLUDING CONJUGATED THERAPY ENHANCERS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-07-18 | — | — | US | disclosed |
| US-20240238436-A1 | COMPOSITIONS INCLUDING CONJUGATED THERAPY ENHANCERS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-07-18 | — | — | US | disclosed |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | ELANE 1609/4885MAPT 2513/4885NPC1 4317/4885 |
| US-20240238436-A1 | COMPOSITIONS INCLUDING CONJUGATED THERAPY ENHANCERS | LGMN, LPXN, LY96 | ELANE 1464/4885MAPT 1026/4885NPC1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.